샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784039

정밀 유전체 검사 시장

Precision Genomic Testing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 222 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

정밀 유전체 검사 세계 시장은 2030년까지 423억 달러에 달할 전망

2024년에 167억 달러로 추정되는 정밀 유전체 검사 세계 시장은 2024- 2030년의 분석 기간 동안에 16.7%의 CAGR로 성장하여 2030년에는 423억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 유전체 검사 소모품은 CAGR 18.2%를 기록하며 분석 기간 종료까지 246억 달러에 달할 것으로 예측됩니다. 유전체 검사 기기 부문의 성장률은 분석 기간 동안 CAGR 15.3%로 추정됩니다.

미국 시장은 44억 달러로 추정, 중국은 CAGR 15.7%로 성장 예측

미국의 정밀 유전체 검사 시장은 2024년에 44억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 65억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 15.7%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 15.6%와 14.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.1%로 성장할 것으로 예측됩니다.

세계의 정밀 유전체 검사 시장 - 주요 동향과 촉진요인 정리

정밀 유전체 검사는 어떻게 의료를 변화시킬 것인가?

정밀 유전체 검사는 개인별 맞춤 진단, 표적 치료, 질병의 조기 발견을 가능하게함으로써 현대 의학에 혁명을 일으키고 있습니다. 개인의 유전자 구성을 분석함으로써 의료진은 유전적 변이에 따라 치료를 조정하여 환자의 결과를 크게 개선할 수 있습니다. 이 접근법은 특히 종양학, 희귀질환, 약리유전체학, 생식의학 분야에서 큰 영향을 미치고 있으며, 유전적 인사이트이 치료 결정에 중요한 역할을 하고 있습니다.

차세대 염기서열분석기(NGS), 크리스퍼(CRISPR) 기반 유전자 편집, AI 기반 바이오인포매틱스의 확대로 다양한 의료 분야에서 정밀유전체 검사의 도입이 가속화되고 있습니다. 전장유전체 염기서열 분석(WGS), 전 엑솜 염기서열 분석(WES), 액체 생검 기술의 발전으로 진단의 정확도가 향상되고, 유전체 검사가 보다 친숙하고 비용 효율성이 높아졌습니다. 유전자 연구가 계속 진화하는 가운데, 단백질체학 및 대사체학을 포함한 멀티오믹스 접근법의 통합은 정밀의료 애플리케이션을 더욱 정교하게 만들고 있습니다.

정밀 유전체 검사 성장을 견인하는 시장 동향은?

정밀 유전체 검사 시장을 형성하는 가장 중요한 트렌드 중 하나는 맞춤형 의료에 대한 수요 증가입니다. 유전자 차이가 약물 반응에 영향을 미친다는 인식이 확산되면서 유전자 프로파일을 기반으로 개인에게 가장 효과적인 약물을 결정하는 약물유전체학(pharmacogenomics)이 확대되고 있습니다. 이는 유전적 요인이 치료 효과에 큰 영향을 미치는 종양학, 순환기학, 신경학 등의 분야에서 특히 중요합니다.

또 다른 중요한 트렌드는 DTC(Direct-to-Consumer) 유전자 검사의 채택이 증가하고 있다는 점입니다. 가계, 질병 위험도 평가, 생활습관 추천을 위한 가정용 유전체 검사 키트를 제공하는 기업들이 인기를 끌며 시장 확대의 원동력이 되고 있습니다. 그러나 규제 당국의 감시와 데이터 프라이버시에 대한 윤리적 우려는 이 분야의 중요한 과제로 남아있습니다.

AI와 빅데이터 분석의 발전도 유전체 검사의 전망을 바꾸고 있습니다. 방대한 유전체 데이터 해석에 머신러닝 알고리즘이 사용되어 질병 위험 예측과 바이오마커 탐색의 정확도가 향상되고 있습니다. 또한, 클라우드 기반 유전체 데이터베이스는 대규모 유전자 연구를 촉진하고 복잡한 질병과 잠재적 치료 표적에 대한 연구를 가속화하고 있습니다.

정밀 유전체 검사 도입을 선도하고 있는 지역은?

북미가 정밀유전체 검사 시장을 독점하고 있으며, 강력한 연구 자금, 맞춤형 의료의 높은 채택률, 고도의 헬스케어 인프라가 그 원동력이 되고 있습니다. 미국은 유전체학 연구에 대한 막대한 투자, All of Us Research Program과 같은 정부 이니셔티브, 바이오기업과 학계의 협업으로 선도하고 있습니다.

유럽은 규제 당국의 지원, 민관 파트너십, 유전자 검사의 임상적 이점에 대한 인식이 높아짐에 따라 주요 기업으로 부상하고 있습니다. 독일, 영국, 프랑스 등의 국가들은 환자 치료를 개선하기 위해 유전체 데이터를 헬스케어 시스템에 통합하는 데 중점을 두고 정밀의료에 대한 노력을 기울이고 있습니다.

아시아태평양에서는 생명공학에 대한 투자 증가, 의료 서비스 접근성 확대, 정밀 의료를 촉진하는 정부 이니셔티브에 힘입어 유전체 검사가 빠르게 성장하고 있습니다. 중국, 일본, 한국은 유전체 데이터 수집 및 분석에 특화된 국가 프로그램을 가지고 있으며, 이 지역의 유전체 연구 노력을 주도하고 있습니다. 한편, 라틴아메리카와 중동의 신흥 시장에서도 점차 정밀 유전체 검사 도입이 진행되고 있지만, 높은 비용과 제한된 인프라 등의 문제가 여전히 보급의 걸림돌로 작용하고 있습니다.

정밀 유전체 검사 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

시장 성장의 주요 촉진요인 중 하나는 유전성 질환과 암, 신경퇴행성 질환, 심혈관질환 등 복합 질환의 유병률 증가입니다. 헬스케어에서 조기 발견과 위험 평가가 더욱 중요해짐에 따라, 유전체 검사는 예방 대책과 정밀 치료의 지침으로 필수적인 역할을 하고 있습니다.

비용 효율적인 초고속 시퀀싱 기술 개발 등 시퀀싱 플랫폼의 기술 발전으로 유전체 검사가 더욱 친숙해지고 있습니다. 휴대용 시퀀싱 장치와 자동화된 워크플로우의 등장은 정밀의료의 범위를 전문 검사실뿐만 아니라 임상 현장과 현장 진단까지 더욱 확장하고 있습니다.

규제 당국의 지원과 자금 지원 이니셔티브도 시장 도입을 가속화하고 있습니다. 세계 각국 정부는 국가 유전체 데이터베이스와 정밀의료 프로그램에 투자하고, 의료 서비스 제공자, 연구기관, 생명공학 기업 간의 협력을 촉진하고 있습니다. 또한, 유전체 검사에 대한 보험급여 정책도 진화하고 있어 유전체 기반 진단에 대한 환자의 접근성과 경제성이 향상되고 있습니다.

유전체학 분야가 계속 발전하고 있는 가운데, AI, 클라우드 컴퓨팅, 분자생물학의 융합은 정밀 유전체 검사 능력을 더욱 향상시킬 것으로 보입니다. 질병 관리, 의약품 개발, 예방 의료를 재정의할 수 있는 잠재력을 지닌 이 시장은 전 세계 맞춤형 의료의 미래를 형성하며 크게 성장할 태세를 갖추고 있습니다.

부문

유형(유전체 검사 소모품, 유전체 검사 기기, 유전체 검사 서비스), 기술 유형(차세대 시퀀싱 기술, 중합효소 연쇄 반응 기술, 마이크로어레이 기술, 생어 시퀀싱 기술, CRISPR/CAS 시스템 기술, 기타 기술 유형), 용도(종양학 용도, 심혈관질환 용도, 신경질환 용도, 생식 의료 용도, 희귀질환 용도, 기타 용도), 최종 용도(병원·클리닉 최종 용도, 진단 연구소 최종 용도, 연구·학술기관 최종 용도, 기타 최종 용도)

조사 대상 기업 사례

  • 23andMe
  • Ambry Genetics
  • BGI Genomics
  • Centogene N.V.
  • Color Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • Fulgent Genetics
  • GeneDx
  • Genomic Health(a subsidiary of Exact Sciences)
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Oxford Nanopore Technologies
  • Qiagen
  • Thermo Fisher Scientific

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

ksm 25.08.11

Global Precision Genomic Testing Market to Reach US$42.3 Billion by 2030

The global market for Precision Genomic Testing estimated at US$16.7 Billion in the year 2024, is expected to reach US$42.3 Billion by 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomic Testing Consumables, one of the segments analyzed in the report, is expected to record a 18.2% CAGR and reach US$24.6 Billion by the end of the analysis period. Growth in the Genomic Testing Equipment segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 15.7% CAGR

The Precision Genomic Testing market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 15.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Precision Genomic Testing Market - Key Trends & Drivers Summarized

How Is Precision Genomic Testing Transforming Healthcare?

Precision genomic testing is revolutionizing modern medicine by enabling personalized diagnostics, targeted therapies, and early disease detection. By analyzing an individual's genetic makeup, healthcare providers can tailor treatments based on genetic variations, significantly improving patient outcomes. This approach is particularly impactful in oncology, rare diseases, pharmacogenomics, and reproductive health, where genetic insights play a crucial role in treatment decisions.

The expansion of next-generation sequencing (NGS), CRISPR-based gene editing, and AI-driven bioinformatics has accelerated the adoption of precision genomic testing across various medical fields. Advances in whole genome sequencing (WGS), whole exome sequencing (WES), and liquid biopsy techniques are enhancing diagnostic accuracy, making genomic testing more accessible and cost-effective. As genetic research continues to evolve, the integration of multi-omics approaches-including proteomics and metabolomics-is further refining precision medicine applications.

What Market Trends Are Driving Growth in Precision Genomic Testing?

One of the most significant trends shaping the precision genomic testing market is the increasing demand for personalized medicine. The growing recognition that genetic differences influence drug response has fueled the expansion of pharmacogenomics, which helps determine the most effective medications for individuals based on their genetic profiles. This is particularly important in fields such as oncology, cardiology, and neurology, where genetic factors significantly impact treatment efficacy.

Another key trend is the rising adoption of direct-to-consumer (DTC) genetic testing. Companies offering at-home genomic testing kits for ancestry, disease risk assessment, and lifestyle recommendations have gained popularity, driving market expansion. However, regulatory scrutiny and ethical concerns regarding data privacy remain key challenges in this sector.

Advancements in AI and big data analytics are also transforming the genomic testing landscape. Machine learning algorithms are being used to interpret vast amounts of genomic data, improving the accuracy of disease risk prediction and biomarker discovery. Additionally, cloud-based genomic databases are facilitating large-scale genetic studies, accelerating research into complex diseases and potential therapeutic targets.

Which Regions Are Leading in Precision Genomic Testing Adoption?

North America dominates the precision genomic testing market, driven by strong research funding, high adoption of personalized medicine, and advanced healthcare infrastructure. The United States leads the way with significant investments in genomics research, government initiatives such as the All of Us Research Program, and collaborations between biotech firms and academic institutions.

Europe is also a key player, benefiting from regulatory support, public-private partnerships, and growing awareness of genetic testing’s clinical benefits. Countries like Germany, the UK, and France are advancing precision medicine initiatives, with an emphasis on integrating genomic data into healthcare systems to improve patient care.

Asia-Pacific is experiencing rapid growth in genomic testing, fueled by increasing investments in biotechnology, expanding healthcare access, and government initiatives promoting precision medicine. China, Japan, and South Korea are leading the region’s genomic research efforts, with national programs dedicated to genomic data collection and analysis. Meanwhile, emerging markets in Latin America and the Middle East are gradually adopting precision genomic testing, although challenges such as high costs and limited infrastructure remain barriers to widespread implementation.

The Growth in the Precision Genomic Testing Market Is Driven by Several Factors

One of the primary drivers of market growth is the increasing prevalence of genetic disorders and complex diseases such as cancer, neurodegenerative conditions, and cardiovascular diseases. As early detection and risk assessment become more critical in healthcare, genomic testing is playing an essential role in guiding preventative measures and precision therapies.

Technological advancements in sequencing platforms, including the development of cost-efficient and ultra-fast sequencing techniques, are making genomic testing more accessible. The emergence of portable sequencing devices and automated workflows is further expanding the reach of precision medicine beyond specialized laboratories to clinical settings and point-of-care diagnostics.

Regulatory support and funding initiatives are also accelerating market adoption. Governments worldwide are investing in national genomic databases and precision medicine programs, promoting collaboration between healthcare providers, research institutions, and biotech companies. Additionally, reimbursement policies for genetic testing are evolving, improving affordability and patient access to genomic-based diagnostics.

As the field of genomics continues to advance, the convergence of AI, cloud computing, and molecular biology will further enhance the capabilities of precision genomic testing. With its potential to redefine disease management, drug development, and preventative healthcare, the market is poised for substantial growth, shaping the future of personalized medicine worldwide.

SCOPE OF STUDY:

The report analyzes the Precision Genomic Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Genomic Testing Consumables, Genomic Testing Equipment, Genomic Testing Services); Technology Type (Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology, Other Technology Types); Application (Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • 23andMe
  • Ambry Genetics
  • BGI Genomics
  • Centogene N.V.
  • Color Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • Fulgent Genetics
  • GeneDx
  • Genomic Health (a subsidiary of Exact Sciences)
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Oxford Nanopore Technologies
  • Qiagen
  • Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Precision Genomic Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Personalized Medicine Accelerates Adoption of Precision Genomic Testing
    • Increasing Awareness of Genetic Risk Factors for Disease Drives Growth in Precision Genomic Testing Applications
    • Surge in Preventive Healthcare and Early Disease Detection Expands Market Opportunity for Genomic Testing Solutions
    • Technological Advancements in CRISPR and Gene Editing Propel the Growth of Precision Genomic Testing
    • Growth in Direct-to-Consumer Genetic Testing Services Generates New Market Opportunities for Genomic Testing Providers
    • Rising Prevalence of Chronic Diseases and Cancer Accelerates Demand for Genomic Testing in Disease Prevention
    • Expansion of Genomic Research and Advancements in Bioinformatics Drives Innovation in Precision Genomic Testing
    • Increased Investment in Genomic Data Integration Technologies Strengthens the Case for Genomic Testing in Healthcare
    • Growing Focus on Pharmacogenomics and Tailored Drug Therapies Expands Market Demand for Genomic Testing Solutions
    • Rising Healthcare Expenditure Globally Accelerates Adoption of Precision Genomic Testing in Clinical Practice
    • Growing Popularity of Genetic Testing for Ancestry and Health Traits Drives Market Expansion
    • Integration of Artificial Intelligence and Machine Learning in Genomic Data Analysis Strengthens Adoption of Precision Genomic Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Precision Genomic Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Precision Genomic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Precision Genomic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Genomic Testing Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Genomic Testing Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Genomic Testing Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Genomic Testing Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Genomic Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Genomic Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Neurological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Neurological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Reproductive Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Reproductive Health Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Rare Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Rare Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Next-Generation Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Next-Generation Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Polymerase Chain Reaction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Microarray Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Microarray Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Sanger Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Sanger Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for CRISPR / CAS Systems Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World 6-Year Perspective for CRISPR / CAS Systems Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Technology Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World 6-Year Perspective for Other Technology Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 42: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: USA 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 48: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: USA 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Canada 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • JAPAN
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 64: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Japan 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • CHINA
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 66: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: China 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: China 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • EUROPE
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Precision Genomic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 82: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Europe 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • FRANCE
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 84: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: France 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 90: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: France 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • GERMANY
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Germany 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • ITALY
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 106: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Italy 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • UNITED KINGDOM
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 108: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: UK 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 114: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: UK 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of World 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 138: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of World 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제